Sign inJoin waitlistJoin the waitlist

Matthew Mirsky

Track Leader · Case Western Reserve University/University Hospitals Cleveland Medical Center

Credentials: · · ·

History

Hematology and Medical Oncology
Case Western Reserve University/University Hospitals Cleveland Medical Center
2021–2024
Internal Medicine
Case Western Reserve University/University Hospitals Cleveland Medical Center
2018–2021
Univ of Toledo Coll of Med
2014–2018
University Of Wisconsin-Madison
2005–2009

Research

JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes
Journal of General Virology · 2012 · 31 citations
Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy: Using Explorys in the MS Population
International Journal of MS Care · 2016 · First of 3 authors · 23 citations
Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis
JAMA Oncology · 2024 · 16 citations

Debora Bruno
5 papers
Ankit Mangla
4 papers
IS
Iris Sheng
4 papers
Afshin Dowlati
3 papers
Luke Rothermel
3 papers
Melinda Hsu
3 papers
Richard Hoehn
3 papers
Jenny Gong
2 papers · 2 as a resident
Katherine Myers
2 papers · 2 as a resident
Lauren Chiec
2 papers
Qian Wang
2 papers
AR
Alexander Rae-Grant
1 paper

Clinical trials

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2026–2027
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Site PI · Recruiting · Phase 1
Whitehawk Therapeutics, Inc.
2025–2028
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
Site PI · Recruiting · Phase 3
ImmunityBio, Inc.
2025–2029